RISK-BENEFIT ANALYSIS AND CASE-STUDY ON TRIBUTYL TIN

被引:3
|
作者
MOORE, L
POSTLE, M
机构
[1] Risk and Policy Analysts Limited (RPA), Loddon, Norfolk NR14 6JL, Warren House, Beccles Road
关键词
D O I
10.1016/0964-8305(94)90097-3
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The Risk-Benefit Analysis (RBA) methodology was developed for the Department of the Environment to assist in the evaluation of regulatory choices concerning hazardous chemicals. RBA considers the risks (human and environmental) and benefits (direct and indirect) associated with the use of a hazardous substance and aims to express these in monetary terms. Through detailed consideration of the existing regulatory regime and the effects of possible regulatory changes, RBA highlights (and quantifies) the trade-offs which would be involved. The tributyl tin (TBT) case study considered the use of TBT in antifouling paints. Through the application of the RBA methodology it looked at the impact (in the UK and the EC) of a ban on the use of TBT and of stricter controls at docks involved in the repainting of ships. Valuation of the economic benefits associated with the use of TBT enabled the risks associated with its use to be implicity valued.
引用
收藏
页码:401 / 412
页数:12
相关论文
共 50 条
  • [1] Risk-benefit analysis
    Mossman, KL
    [J]. HEALTH PHYSICS, 2002, 82 (05): : 750 - 750
  • [2] Risk-benefit analysis
    Wilson, R.
    Crouch, E.A.C.
    [J]. Physics Today, 2002, 55 (10)
  • [3] RISK-BENEFIT ANALYSIS
    ZENCEY, M
    [J]. ATLANTIC, 1979, 243 (04): : 37 - 37
  • [4] Risk-benefit ratio or risk-benefit nonsense?
    Ernst, E
    Resch, KL
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1996, 49 (10) : 1203 - 1204
  • [5] Risk-benefit analysis of micronutrients
    Renwick, AG
    Flynn, A
    Fletcher, RJ
    Müller, DJG
    Tuijtelaars, S
    Verhagen, H
    [J]. FOOD AND CHEMICAL TOXICOLOGY, 2004, 42 (12) : 1903 - 1922
  • [6] THE FALLACIES OF RISK-BENEFIT ANALYSIS
    SAMUELS, SW
    [J]. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1979, 329 (OCT) : 267 - 273
  • [7] PENTAMIDINE - A RISK-BENEFIT ANALYSIS
    WISPELWEY, B
    PEARSON, R
    [J]. DRUG SAFETY, 1990, 5 (03) : 212 - 219
  • [8] A risk-benefit analysis of vaccination
    Heininger, Ulrich
    [J]. VACCINE, 2009, 27 : G9 - G12
  • [9] BIAS IN RISK-BENEFIT ANALYSIS
    MAZUR, A
    [J]. TECHNOLOGY IN SOCIETY, 1985, 7 (01) : 25 - 30
  • [10] Symmetrical analysis of risk-benefit
    Warren, John B.
    Day, Simon
    Feldschreiber, Peter
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 74 (05) : 757 - 761